Inclusion Criteria

Selection of Patients - Eligibility Criteria

- Patients will be at least 18 years of age.

- Patients will be experiencing moderate to severe peripheral neuropathic pain

- Patients may be on chronic adjuvant pain medications such as antidepressants but must
be on stable doses for at least one week prior to admission.

- Patients may be taking concurrent opioids but they must be willing to allow us to
monitor their opioid use while on the trial.

- Chronic peripheral neuropathic pain will be defined as pain of 3 or more months
duration which began in association with chemotherapy.

- Patient's will have bilateral peripheral neuropathic pain symptoms primarily
involving the feet

- Patients may have breast cancer at any stage and no disease specific evaluations will
be taken or measured.

- Able to read and speak English and provide informed consent.

- Patients may be receiving chemotherapy as long as the agents are not known to cause a
peripheral neuropathy.

- Will not concurrently use gabapentin or pregabalin or must be willing to wean
offtheir anti-convulsant medications prior to starting the trial.

- Patients may have diabetes mellitus (type 1 or 2) as long as there is no preexisting
neuropathy.

Exclusion criteria:

- Patients will not have secondary cause of neuropathic pain including:
HIV/AIDS,traumatic injury, or a personal history of non chemotherapy-induced
neuropathy.

- Patients will not have a history of major depression or severe anxiety. This will be
evaluated at the initial visit

- Women of childbearing age will agree to take measures to prevent pregnancy and will
not breast-feed while on the study medication. Women who are currently pregnant will
not be invited to participate in this study.

- Patients will not have a history of seizures.

- Patients cannot be currently receiving antibiotic therapy for tuberculosis (e.g.
isoniazid).